DHUNE

CHU La Timone

Département de Pharmacologie Clinique

264 Rue Saint-Pierre  
13385 Marseille Cedex 5
FRANCE
 

 

Mail :

dhune-contact@univ-amu.fr 

 

Direction :

Pr Olivier BLIN

Directeur du Centre de Pharmacologie Clinique et de Pharmacovigilance 

 

Chargée de mission :

Lisa OTTEN

 

 

    

DHUNE, Centre d’excellence pour les Maladies Neurodégénératives
DHUNE, Centre d’excellence pour les Maladies Neurodégénératives

DHUNE

 

DHU for care, research and university-hospital teaching

N for neurodegenerative diseases and aging

E for Euro-Méditerranée

 

 

DHUNE is part of the French National Plan 2014-2019 against Neurodegenerative Diseases in which several of its members actively participate

 

  • 4 Institutions: Aix-Marseille University (AMU), the Public Hospital Assistance of Marseille (AP-HM), the National Institute of Medical Research (Inserm) and the National Centre for Scientific Research (CNRS).  

  • 5 Hospital Units  that gather the leading experts as well as the national reference centres that are labelled for neurodegenerative diseases   

 

  • 34 teams and more than 100 permanent researchers in neuroscience and human and social sciences 

 

  • 17 local industrial partners (ICDD, Neuroservice, Neuron experts, Provetech, Vect-Horus, Qualissima, Neuro-Sys, Neurochlore, B&A Therapeutics, Epiona, Horus Pharma, Global Stim, CilCare, Amylgen, SigmaThera, Inflectis, Ktalyse) 

 

  • 2 international pharmaceutical industries: Ipsen, Sanofi

 

  • 5 patient associations (France Alzheimer, CISS, France Parkinson, PACASEP, UNISEP), from the networks of care in neurodegenerative diseases

 

  • 3 prestigious international university partners: Imperial College (Londres), Technion (Haifa) and Neurodegenerative Disorders Network (Inde)


The DHUNE centre is part of 7 French centres that have been labelled as excellence centre by AVIESAN (National Alliance for Life Sciences and Health) within the network of Centres of Excellence in Neurodegeneration (CoEN) in Europe and Canada.

 

Furthermore, DHUNE is labelled as FHU (University Hospital Federation).

This label is part of the 2014-2019 plan on neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, multiple sclerosis...). It enables DHUNE to participate in the call for projects from the RHU (Hospital University Research in Health) from the National Research Agency (ANR) and thereby benefit from financial support of a value between 5 and 10 million euros for 5 years of research.